Market closedNon-fractional
Arcus Biosciences/RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Ticker
RCUS
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology
Headquarters
Hayward, United States
Employees
577
Website
www.arcusbio.com
RCUS Metrics
BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$2.99
EPS
0.89
Beta
-
Dividend rate
Price and volume
Market cap
$1.4B
Beta
0.89
Financial strength
Current ratio
5.216
Quick ratio
5.074
Long term debt to equity
2.829
Total debt to equity
4.385
Interest coverage (TTM)
-125.00%
Management effectiveness
Return on assets (TTM)
-12.27%
Return on equity (TTM)
-35.35%
Valuation
Price to revenue (TTM)
4.886
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-4.927
Growth
Revenue change (TTM)
99.16%
Earnings per share change (TTM)
-22.40%
3-year revenue growth (CAGR)
40.62%
3-year earnings per share growth (CAGR)
2.55%
What the Analysts think about RCUS
Analyst Ratings
Majority rating from 12 analysts.
RCUS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$145M
367.74%
Net income
-$4M
-95.06%
Profit margin
-2.75%
-98.95%
RCUS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.04
-$0.94
-$1.08
-$0.05
-
Expected
-$1.10
-$1.13
-$1.02
-$0.95
-$1.13
Surprise
-5.33%
-16.72%
5.46%
-94.74%
-
RCUS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $1.4B as of July 27, 2024.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of July 27, 2024.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Arcus Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.